Just a few neoantigens may be enough for T cells to control

In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.

Turning cold tumors into hot tumors by improving T-cell infiltration

What is T cell therapy?

Harnessing the Immune System To Treat Cancer

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Molecular Cancer

Frontiers Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

not-all-neoantigens-are-created-equal

Cancers, Free Full-Text

Developing neoantigen-targeted T cell–based treatments for solid tumors

The mechanisms of vaccines and neoantigens in the T cell immune

Pharmaceuticals, Free Full-Text

Neoantigens: promising targets for cancer therapy

Biologists identify new targets for cancer vaccines, MIT News

Recognition of tumor neoantigens by CD8 + T cells. receptors on CD8 + T

Cancers, Free Full-Text

What is neoantigen-based therapy?

Why Are Some Organs more Susceptible to Cancer?

Groupe Génétique et Cancer - La Recherche Unicancer

Recent Trends in Breast Cancer Incidence and Mortality • The Center for Restorative Breast Surgery

Cancer in 2023 AACR Cancer Progress Report 2023

Sport: les effets bénéfiques de l'activité physique en prévention et quand on lutte contre un cancer